MaxCyte Inc. closed a share placement to raise about £20 million in gross proceeds for its CARMA platform.
The company issued 7,275,000 shares at £2.75 apiece with Panmure Gordon acting as the financial adviser, nominated adviser and broker to the company.
Completion of the placement is subject to shareholder approval.
The CARMA platform is meant to help the company develop treatments for ovarian cancer and acute myeloid leukemia, a type of blood cancer. It will also be used to develop treatments for other indications.